• Mitsubishi Tanabe Pharma Canada Announces That Company’s Oral Treatment Formulation For Amyotrophic Lateral Sclerosis (Als) Has Been Added To The Provincial Drug Plan In Manitoba
  

  ---

• Mitsubishi Tanabe Pharma Canada Announces Oral Treatment Formulation For Amyotrophic Lateral Sclerosis (Als) Now Eligible For Coverage Through Veteran Affairs Canada And Indigenous Services Canada
  

  ---

• Mitsubishi Tanabe Pharma Canada Celebrates Five Years in Canada Supporting and Committed to People Living with ALS
  

  ---

• Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plans in Prince Edward Island, Newfoundland and Labrador
  

  ---

• Canadian-Developed AI Technology Aims to Support Early Detection of ALS
  

  ---

• Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) has been Added to the Provincial Drug Plans in Saskatchewan
  

  ---

• Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) has been Added to the Provincial Drug Plans in New Brunswick and Nova Scotia
  

  ---

• Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) has been Added to the Provincial Drug Plan in British Columbia
  

  ---

• Mitsubishi Tanabe Pharma Canada Announces that Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) has been Added to the Provincial Drug Plan in Québec
  

  ---

• Mitsubishi Tanabe Pharma Canada Announces Collaboration with the CNDR on First Canadian Real-World Evidence Study of RADICAVA® IV (edaravone) Survival Benefits in ALS
  

  ---